159 related articles for article (PubMed ID: 35013795)
1. Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.
Jiang L; Ye L; Ma L; Ren Y; Zhou X; Mei C; Xu G; Yang H; Lu C; Luo Y; Zhu S; Wang L; Shen C; Yang W; Zhang Q; Wang Y; Lang W; Han Y; Jin J; Tong H
J Cancer Res Clin Oncol; 2022 Apr; 148(4):845-856. PubMed ID: 35013795
[TBL] [Abstract][Full Text] [Related]
2. Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes.
Jiang L; Wang L; Shen C; Zhu S; Lang W; Luo Y; Zhang H; Yang W; Han Y; Ma L; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
Am J Cancer Res; 2020; 10(12):4476-4487. PubMed ID: 33415012
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
[TBL] [Abstract][Full Text] [Related]
4. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
[TBL] [Abstract][Full Text] [Related]
5. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.
Belickova M; Vesela J; Jonasova A; Pejsova B; Votavova H; Merkerova MD; Zemanova Z; Brezinova J; Mikulenkova D; Lauermannova M; Valka J; Michalova K; Neuwirtova R; Cermak J
Oncotarget; 2016 Jun; 7(24):36266-36279. PubMed ID: 27167113
[TBL] [Abstract][Full Text] [Related]
7. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Montalban-Bravo G; Kanagal-Shamanna R; Benton CB; Class CA; Chien KS; Sasaki K; Naqvi K; Alvarado Y; Kadia TM; Ravandi F; Daver N; Takahashi K; Jabbour E; Borthakur G; Pemmaraju N; Konopleva M; Soltysiak KA; Pierce SR; Bueso-Ramos CE; Patel KP; Kantarjian H; Garcia-Manero G
Blood Adv; 2020 Feb; 4(3):482-495. PubMed ID: 32027746
[TBL] [Abstract][Full Text] [Related]
8. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
9. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
Wang W; Routbort MJ; Tang Z; Ok CY; Patel KP; Daver N; Garcia-Manero G; Medeiros LJ; Wang SA
Eur J Haematol; 2017 Dec; 99(6):536-543. PubMed ID: 28926144
[TBL] [Abstract][Full Text] [Related]
10. Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients.
Lee WH; Lin CC; Tsai CH; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
Am J Hematol; 2022 Dec; 97(12):1589-1598. PubMed ID: 36109871
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Shah MV; Tran ENH; Shah S; Chhetri R; Baranwal A; Ladon D; Shultz C; Al-Kali A; Brown AL; Chen D; Scott HS; Greipp P; Thomas D; Alkhateeb HB; Singhal D; Gangat N; Kumar S; Patnaik MM; Hahn CN; Kok CH; Tefferi A; Hiwase DK
Blood Cancer J; 2023 Apr; 13(1):51. PubMed ID: 37041128
[TBL] [Abstract][Full Text] [Related]
12. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Tefferi A; Fleti F; Chan O; Al Ali NH; Al-Kali A; Begna KH; Foran JM; Badar T; Khera N; Shah M; Hiwase D; Padron E; Sallman DA; Pardanani A; Arber DA; Orazi A; Reichard KK; He R; Ketterling RP; Gangat N; Komrokji R
Br J Haematol; 2024 Apr; 204(4):1243-1248. PubMed ID: 38083865
[TBL] [Abstract][Full Text] [Related]
13. Analysis of clinical and molecular features of MDS patients with complex karyotype in China.
Ren Y; Mei C; Ye L; Luo Y; Zhou X; Yang H; Lin P; Xu W; Ma L; Jin J; Tong H
Blood Cells Mol Dis; 2019 Mar; 75():13-19. PubMed ID: 30530101
[TBL] [Abstract][Full Text] [Related]
14. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.
Zhao D; Eladl E; Zarif M; Capo-Chichi JM; Schuh A; Atenafu E; Minden M; Chang H
Cancer Med; 2023 Mar; 12(6):6511-6522. PubMed ID: 36394085
[TBL] [Abstract][Full Text] [Related]
16. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
[No Abstract] [Full Text] [Related]
17. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.
Shen K; Hu DY; Zhang ZB; Guo YS; Zhang FH; Chen SN
Int J Lab Hematol; 2023 Jun; 45(3):344-352. PubMed ID: 36860196
[TBL] [Abstract][Full Text] [Related]
18.
Bomben R; Rossi FM; Vit F; Bittolo T; D'Agaro T; Zucchetto A; Tissino E; Pozzo F; Vendramini E; Degan M; Zaina E; Cattarossi I; Varaschin P; Nanni P; Berton M; Braida A; Polesel J; Cohen JA; Santinelli E; Biagi A; Gentile M; Morabito F; Fronza G; Pozzato G; D'Arena G; Olivieri J; Bulian P; Pepper C; Hockaday A; Schuh A; Hillmen P; Rossi D; Chiarenza A; Zaja F; Di Raimondo F; Del Poeta G; Gattei V
Clin Cancer Res; 2021 Oct; 27(20):5566-5575. PubMed ID: 34285062
[TBL] [Abstract][Full Text] [Related]
19. Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
Dutta S; Moritz J; Pregartner G; Thallinger GG; Brandstätter I; Lind K; Rezania S; Lyssy F; Reinisch A; Zebisch A; Berghold A; Wölfler A; Sill H
Ann Hematol; 2022 Apr; 101(4):837-846. PubMed ID: 35083527
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
Short NJ; Montalban-Bravo G; Hwang H; Ning J; Franquiz MJ; Kanagal-Shamanna R; Patel KP; DiNardo CD; Ravandi F; Garcia-Manero G; Takahashi K; Konopleva M; Daver N; Issa GC; Andreeff M; Kantarjian H; Kadia TM
Blood Adv; 2020 Nov; 4(22):5681-5689. PubMed ID: 33211826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]